Boehringer’s Olodaterol Gains Advisory Committee Support, But May See Indication Clarified
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee voted 15-1 that efficacy and safety had been shown, but said the label should not imply it is a treatment for chronic bronchitis and emphysema, just airway obstruction in those conditions, as well as COPD.